If you take Zepbound or Mounjaro, you may eventually have access to treatments specifically designed to help preserve muscle while you lose weight. And you may already be hearing from your favorite GLP-1 influencer that the FDA just approved apitegromab, now sold as ISEMBYLD, the latest muscle-targeting drug to reach the market.

Here’s the catch: the app…